Pediatric Oncology | Specialty

Managing Thromboembolic Events in Pediatric Cancer

September 23rd 2017

Guy Young, MD, discussed the use of anticoagulants in managing thromboembolic events in pediatric cancer.

Dr. Young Discusses Thromboembolic Events in Pediatric Cancer

September 21st 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses the occurrence of thromboembolic events in pediatric cancer.

Update Sustains Tisagenlecleucel Activity in Pediatric ALL

September 20th 2017

Tisagenlecleucel (Kymriah) induced a complete remission with complete or incomplete hematologic recovery in 83% of pediatric, adolescent, and young adult patients with acute lymphoblastic lymphoma.

Expert Discusses Strategies for Advancing Pediatric ALL Care

September 20th 2017

The effort to improve outcomes in pediatric acute lymphoblastic leukemia should follow insight provided by next-generation sequencing and appropriate use of minimal residual disease criteria.

Expert Discusses Approval of First CAR T-Cell Therapy

September 18th 2017

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

Lower Dose ATLG Safer, More Effective in Children With Hematologic Malignancies

September 15th 2017

A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin was associated with similar graft-vs-host-disease, less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.

Early Administration of Cytarabine May Improve Survival in Pediatric ML-DS

September 13th 2017

Administering high-dose cytarabine to children with myeloid leukemia of Down syndrome during the second chemotherapy induction cycle resulted in improved event-free survival and overall survival compared to results observed in previous research studies.

FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy

August 30th 2017

The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

Arsenic Trioxide Consolidation Effective in Pediatric Acute Promyelocytic Leukemia

August 21st 2017

Arsenic trioxide consolidation was effective and safe in newly diagnosed pediatric patients with acute promyelocytic leukemia, allowing a significant reduction in cumulative anthracycline doses

Crizotinib Induces High Response Rates in Pediatric ALCL, IMT

August 18th 2017

In a small study of pediatric patients with relapsed/refractory ALK-positive anaplastic large cell lymphoma, treatment with 165 mg/m2 of crizotinib (Xalkori) was associated with an overall response rate of 83%

Biomarker Basics: A Look at MSI's Growing Role

August 2nd 2017

The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.

FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer

August 1st 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

FDA Approves Ipilimumab for Pediatric Melanoma

July 24th 2017

The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.

Expert Discusses State of CAR T-Cell Therapy in ALL

July 13th 2017

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL

July 12th 2017

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

FDA Grants Dasatinib Priority Review for Children With Ph+ Chronic Phase CML

July 11th 2017

The FDA has accepted a supplemental new drug application for dasatinib (Sprycel) for use in children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML).

CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL

June 25th 2017

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.

Making Strides Against a Rare Disease: Renal Medullary Carcinoma in Focus

June 8th 2017

Renal medullary carcinoma is a rare but devastating tumor type almost exclusively affecting young adults carrying 1 copy of hemoglobin beta (HBB) harboring the A17T mutation (HbS).

Late Effects of Childhood Cancers Dropping Along With Intensity of Treatments

June 3rd 2017

The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.

Uridine Triacetate for 5-FU or Capecitabine Toxicity

May 30th 2017